BIOASTER, Bio-Rad and Genetic Analysis Collaborate to Develop Novel Microbiome-Based Diagnostics for Metabolic Disorders

BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, announced the initiation of a collaborative program with BIOASTER, Bio- Rad Laboratories, Inc. and Genetic Analysis aimed at evaluating microbial dysbiosis signatures in the field of metabolic disorders.

This project is a unique opportunity for BIOASTER to capitalize on its breakthrough deep and 16S-targeted sequencing technologies and advanced pipelines of data analysis for highlighting new gut microbiome biomarkers of medical added value.

Endocrine and metabolic diseases are among the most common contemporary human afflictions in western countries and particularly in the United States. The high prevalence and incidence of common metabolic disorders such as diabetes and obesity have been confirmed through large population-based studies. Moreover, an increasing number of studies show that deregulation of gut microbiota composition (“dysbiosis”) is associated with onset of metabolic diseases and may impact treatment.

This original collaboration between Bio-Rad, a world leading provider of life science research and clinical diagnostic products, Genetic Analysis, a Norwegian company renowned in microbiome molecular diagnostics and BIOASTER will add an innovative edge of this research program by examining gut microbiota signatures for diagnostics. Genetic Analysis and Bio-Rad previously announced in December 2017 a supply and distribution agreement for Genetic Analysis’s GA-map® clinical test for gut dysbiosis.

This collaborative program illustrates very well BIOASTER’s ambition: bringing togethermultiple partners and complementary expertise for accelerating innovation towards industrialproduct development. We are very proud to be part of this exciting project that will generate new avenues in the field of the microbiome- based diagnostics.

said Nathalie Garçon, CEO & CSO of BIOASTER.

We are delighted to collaborate with BIOASTER and Bio-Rad on this important researchproject”

commented Ronny Hermansen, CEO of Genetic Analysis.

As more and more links arediscovered between the human microbiome and immune status, the need for accurate biomarker-based tests becomes pressing. Genetic Analysis and Bio-Rad have a strong track record along with considerable experience in developing and bringing innovative diagnostic tools to market.

We look forward to working with BIOASTER on this very interesting project

he added.